The macbank statement on the back pain trial stated that it was largely negative.How can they state this without issueing further evidence to substantiate that claim.The lower back trial was based on pain and functional improvement and interventions and not on Anatomical structures as macbank have stated in part of there report.They should explain the trial based evidence on Anatomical negatives if there were any to share holders before making such a claim. Overall the trial had a good success rate as per the trial outcomes.The mesoblast statement claimed that there was an improvement in the Anatomical structure.The trial also enrolled patients who were beyond help after using refractory steroids.Phase 3 on the way.
The macbank statement on the back pain trial stated that it was...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |